Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Lofexidine studied for treatment of opiate withdrawal symptoms in phase III trial

Oct. 11, 2006

European approval for Suboxone for treatment of opioid dependence

Oct. 6, 2006

Alkermes developing oral products for treatment of addiction

Oct. 5, 2006

Champix approved in Europe

Oct. 2, 2006

PharmAthene awarded Department of Defense contract for Protexia development

Sep. 27, 2006

ArmaGen receives grant to develop first nerve gas antidote

Sep. 20, 2006

SBIR grant for Cleveland BioLabs' radioprotector research

Sep. 12, 2006

Aktiv-Dry awarded grant to develop inhalable nicotine vaccine

Sep. 4, 2006

E.U. approval for Exjade

Aug. 30, 2006

Antidote for isotope intoxication reported by Department of Atomic Energy in India

Aug. 8, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...